司美格鲁肽肾病适应症获FDA批准,中国申请已受理

第一财经
29 Jan

因减重而“走红”的GLP-1类降糖药司美格鲁肽再添新适应症。  当地时间1月28日,美国FDA批准诺和诺德司美格鲁肽降糖药用于降低患有慢性肾病(CKD)的糖尿病患者发生肾衰竭和病情恶化的风险,以及因心脏病导致的死亡。该药物也成为首个用于治疗CKD的GLP-1药物。  此次FDA的批准决定基于司美格鲁肽降糖药物的一项后期临床数据,研究表明,司美格鲁肽可将因慢性肾病和重大心脏事件死亡的风险降低24%。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10